Clinical trial
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced…
NCT00003350 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003350 |
|---|---|
| Title | Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma |
| Official title | Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | AIDS-related Kaposi Sarcoma |
| Intervention type | Drug, Other, Procedure |
| Interventions | paclitaxel, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis, quality-of-life assessment |
| Enrollment | 240 |
| Start date | Mar 1, 1999 |
| Primary completion | Mar 1, 2007 |
| First posted | Jul 11, 2003 |
| Last update posted | Jan 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: